Industry top-down
Diagnostics & Research
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
The diagnostics and research industry overall maintained its growth trend, recording a median revenue YoY of 5.41%. Some specialized diagnostics companies, such as Natera, Guardant Health, and Adaptive Biotechnologies, showed high double-digit revenue growth. However, performance varied significantly by company, with some companies like Danaher, Illumina, ICON PLC, and Charles River Laboratories experiencing negative revenue growth. Regarding profitability, EPS YoY also saw Waters Corp, Quest Diagnostics, and Medpace Holdings achieve double-digit growth, while ICON PLC and Charles River Laboratories showed significant declines, indicating a mixed trend across the industry.
- Industry-wide sales growth maintained (median sales YoY 5.41%)
- Some diagnostic companies show high sales growth (e.g., Natera, Guardant Health growing over 20%)
- Profitability indicators show deepening divergence by company (EPS YoY split into extremes)
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| DHRDANAHER CORP /DE/ | FY2026 Q1 | $5.74B | -0.9% | $1.32 | -9.0% | — |
| IDXXIDEXX LABORATORIES INC /DE | FY2026 Q1 | $998.43M | +3.6% | $2.96 | +5.3% | — |
| AAGILENT TECHNOLOGIES, INC. | FY2026 Q1 | $1.68B | +1.4% | $1.11 | -5.9% | — |
| WATWATERS CORP /DE/ | FY2026 Q1 | $662M | +4.0% | $2.03 | +18.0% | — |
| NTRANatera, Inc. | FY2026 Q1 | $501.83M | +36.5% | $-0.50 | — | — |
| IQVIQVIA HOLDINGS INC. | FY2026 Q1 | $3.83B | +2.5% | $1.40 | -10.3% | — |
| ILMNILLUMINA, INC. | FY2026 Q1 | $1.04B | -3.3% | $0.82 | — | — |
| MTDMETTLER TOLEDO INTERNATIONAL INC/ | FY2026 Q1 | $883.74M | — | $7.81 | — | — |
| DGXQUEST DIAGNOSTICS INC | FY2026 Q1 | $2.65B | +12.1% | $1.94 | +12.8% | — |
| LHLABCORP HOLDINGS INC. | FY2026 Q1 | $3.35B | +5.3% | $2.52 | -6.3% | — |
| GHGuardant Health, Inc. | FY2026 Q1 | $203.47M | +20.8% | $-0.77 | — | — |
| MEDPMedpace Holdings, Inc. | FY2026 Q1 | $558.57M | +9.3% | $3.67 | +14.7% | — |
| ICLRICON PLC | FY2025 Q3 | $1.97B | -67.5% | $1.32 | -72.4% | — |
| CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. | FY2026 Q1 | $984.17M | -2.7% | $0.50 | -61.5% | — |
| BLLNBillionToOne, Inc. | FY2026 Q1 | $58.96M | — | $-0.39 | — | — |
| GRALGRAIL, Inc. | FY2026 Q1 | $31.84M | +19.1% | $-3.10 | — | — |
| ADPTAdaptive Biotechnologies Corp | FY2026 Q1 | $52.44M | +25.2% | $-0.20 | — | — |
| PSNLPersonalis, Inc. | FY2026 Q1 | $20.61M | +5.5% | $-0.18 | — | — |
| CDNACareDx, Inc. | FY2026 Q1 | $84.69M | +17.5% | $-0.19 | — | — |
| OPKOPKO HEALTH, INC. | FY2026 Q1 | $149.95M | — | $-0.10 | — | — |
| CSTLCASTLE BIOSCIENCES INC | FY2026 Q1 | $87.99M | +20.6% | $-0.90 | — | — |
| MYGNMYRIAD GENETICS INC | FY2026 Q1 | $195.9M | -3.1% | $0.00 | — | — |
| IMDXInsight Molecular Diagnostics Inc. | FY2026 Q1 | $2.14M | — | $-0.26 | — | — |
| BDSXBIODESIX INC | FY2026 Q1 | $17.96M | +21.2% | $-1.52 | — | — |
| FONRFONAR CORP | FY2023 Q3 | $72.78M | +11.6% | $1.43 | +5.9% | — |
| IDXGINTERPACE BIOSCIENCES, INC. | FY2026 Q1 | $11.52M | +13.1% | $0.06 | -62.5% | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).